Janumet (Metformin Hydrochloride, Sitagliptin)

Metformin Hydrochloride decreases hepatic glucose production and increases peripheral insulin sensitivity. Sitagliptin inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4), which raises incretin hormone levels, leading to glucose‑dependent insulin release and reduced glucagon secretion. The combination offers complementary glucose‑lowering effects.

The appropriate dose of Janumet is determined by the prescribing healthcare professional based on individual patient factors such as renal function, glycemic targets, and concomitant medications. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

Safety of Janumet in pregnancy and lactation has not been established. Generally, the drug is avoided unless the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To order Janumet, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. The team then replies with pricing, availability, shipping details and any required import documentation.

Compared with metformin alone, Janumet adds a DPP‑4 inhibitor, offering greater HbA1c reduction for patients who need additional glucose control. Relative to other DPP‑4 inhibitors, sitagliptin provides a well‑characterized safety profile and once‑daily dosing, while the combination simplifies therapy by merging two mechanisms into a single tablet.

Janumet tablets should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the container tightly closed and out of reach of children. Do not store in bathrooms or near heat sources.

Janumet is taken orally, usually with the evening meal to improve gastrointestinal tolerance. The tablet should be swallowed whole with a glass of water and not crushed or chewed. Patients should follow the dosing schedule prescribed by their healthcare professional.

The most serious risks include lactic acidosis, a rare but potentially fatal metabolic disturbance, and pancreatitis, which presents as severe abdominal pain. Severe hypoglycemia can also occur, especially when combined with insulin or sulfonylureas. Prompt medical attention is required if any of these symptoms develop.

Janumet is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), known hypersensitivity to metformin, sitagliptin, or any component of the tablet, and in individuals with a history of lactic acidosis. It should also be avoided in patients with acute or chronic metabolic acidosis.